New research indicates that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional diet and exercise programs.
Findings released in a prominent health publication demonstrates that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Individuals using such medications must be informed of the danger of rapid rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.
Such speed of regain means a reversion to original mass in about 18 months.
Weighing Approaches
The study, which examined dozens of trials involving thousands of participants, compared the results of GLP-1 agonists with other pills.
Researchers point out that people who shed pounds through dieting usually experience a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Regain
Doctors suggest the mode of action of the jabs is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating a significant risk."
A Lifelong Condition?
The NHS suggest the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, given the high risk of weight regain, the therapy is often long-term.
This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the long-term nature of obesity," akin to managing diseases like diabetes.
User Testimonies
Individuals who have stopped the jabs report a sudden return of cravings.
"It was like a switch activating and you become extremely hungry," described an individual.
This challenge is exacerbated if users have not developed permanent dietary or behavioural modifications during treatment.
Significant Adoption
Recent estimates show that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is greater among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, clinicians caution that while the jabs are effective agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on combined lifestyle changes.